Table 1.
Demographic characteristics of the study participants included in the SBA analysis.
| 1.5/25 µg group (N=19) | 6/100 µg group (N=22) | Control group (N=9) | Total (N=50) | |
|---|---|---|---|---|
| Age (mean ± SD), years | 25.5 ± 6.2 | 27.1 ± 8.0 | 29.4 ± 6.9 | 26.9 ± 7.1 |
| Male, n (%) | 18 (94.7) | 19 (86.4) | 8 (88.9) | 45 (90.0) |
| Female, n (%) | 1 (5.3) | 3 (13.6) | 1 (11.1) | 5 (10.0) |
| Race, n (%) | ||||
| Black | 18 (94.7) | 22 (100.0) | 9 (100.0) | 49 (98.0) |
| White | 1 (5.3) | 0 (0.0) | 0 (0.0) | 1 (2.0) |
SBA, serum bactericidal activity; N, total number of participants; n (%), number (percentage) of participants in each category; SD, standard deviation.;1.5/25 µg group, participants receiving the 1.5/25 µg O antigen/protein vaccine formulation; 6/100 µg group, participants receiving the 6/100 µg O antigen/protein vaccine formulation; Control, participants receiving a quadrivalent meningococcal conjugate vaccine at Day 1 and a vaccine against tetanus, diphtheria, and acellular pertussis at Day 29.